The High Cost of Failure
Drug discovery remains one of the most capital-intensive ventures on earth. Each new molecule faces a long, fragile journey through laboratory work, animal studies, and clinical testing — a path where over 90 per cent of candidates fail before approval. The financial loss is measured in billions; the human cost is measured in years of delay for patients still waiting.
VeriSIM Life has positioned itself at the inflection point between biology and computation. Its BIOiSIM platform replaces many early-stage experiments with predictive simulations — digital twins of animals and humans that forecast how a drug will behave long before a real dose is given.
Dr Jo Varshney, Founder and CEO of VeriSIM Life, describes the change in terms of scale and intent:
“What we’ve built is a simulator that creates digital twins of both animals and humans. These twins let us study how drugs behave in virtual environments before we ever test them in the real world. The idea is to de-risk development by predicting outcomes early, saving time, cost, and lives.”
Quantifying Translational Strength
At the core of this system sits the Translational Index, a proprietary metric that functions like a financial rating for an experimental therapy. Where investors use credit scores to gauge reliability, VeriSIM uses this index to gauge a drug candidate's scientific health and practical feasibility. It quantifies exposure, dose response, genomic variability, and predicted toxicity, translating biology into a comparable risk signal.
Varshney explains the reasoning behind the approach: “The Translational Index enables teams to decide which assets to progress and which to stop early, before spending millions on a weak candidate.”
In effect, BIOiSIM turns a once-intuitive art into a measurable discipline, enabling portfolio managers to compare molecules with the same rigour they bring to financial assets.
Real-World Proof and Tangible Returns
The promise of simulation has been discussed for years; VeriSIM's distinction is execution. Several partners have already advanced programmes beyond Phase 1. At the same time, the company's own lead therapy for pulmonary fibrosis and hypertension reached the Investigational New Drug (IND) stage at roughly one-fifth the usual cost.
“These results show how predictive simulation can change the economics of innovation: you spend smarter, move faster, and reduce waste," Varshney says.
The implications reach beyond internal savings and offer faster progression through the pipeline, which means patients in rare-disease communities see therapies months sooner.
Predicting Failure Before It Happens
Toxicity remains the silent killer of R&D budgets. A single unforeseen safety signal can collapse a multi-year programme. VeriSIM Life built its platform specifically to expose such risks early, particularly in liver toxicity, one of the most common reasons for late-stage failure.
"By combining our understanding of chemistry with physiology and patient variability, we improved prediction accuracy to around 80 per cent, compared with 50 per cent in traditional, data-limited settings," says Varshney.
To achieve that level of precision, BIOiSIM generates synthetic datasets that fill the gaps left by fragmented healthcare data. It is an approach that turns scarcity of information into an opportunity for innovation.
Global Scalability and Regulatory Readiness
One of BIOiSIM’s design principles is portability, and it can operate across regulatory regimes and data-privacy laws without losing compliance or speed. The system relies on anonymised data and adheres to both GDPR in Europe and HIPAA in the United States, allowing global partners to collaborate securely. And the ambition is to make the technology globally scalable in terms of cost, too.
Varshney frames affordability not in terms of licensing costs but of systemic efficiency: "When we talk about affordability, we mean making R&D itself affordable — cutting the time, cost, and effort needed to bring a safe, effective therapy to market. We built the platform from the start to be globally scalable and compliant so that a company anywhere can benefit without reinventing its data infrastructure."
Such design choices position VeriSIM Life for partnerships that cross borders and regulatory silos, a crucial factor as drug pipelines become increasingly multinational.
Designing for Resilience and Reach
Beyond discovery, another goal is to ensure that every successful molecule can move through global supply chains without costly refrigeration or fragility.
“A drug has to travel; it has to reach people wherever they are,” Varshney says. “We focus on stable formulations that don’t depend on the cold chain. Our inhaled product, for example, is highly stable, easy to manufacture, and low-cost. That makes it more resilient and far easier to distribute worldwide.”
By engineering resilience into the molecule itself, BIOiSIM helps companies avoid the supply-chain crises that have plagued the industry since the pandemic.
Embedding Ethics and Sustainability from Day Zero
Perhaps the most radical element of VeriSIM’s model is philosophical. The company views ethical and sustainable design as a first-order principle. Virtual testing reduces the use of animals, lowers risk to early human volunteers, and allows for broader demographic representation in trial planning.
Varshney articulates her mission: “We think about sustainability and ethics from the first day of design, not as an afterthought. By running virtual studies before live ones, we can reduce animal use, minimise human risk, and make trials more inclusive and representative. That’s what we mean when we talk about building an ethical, sustainable model of drug development for the future.”
The effect is to shift the moral baseline of pharmaceutical R&D by aligning profitability, predictability, and responsibility in a single operating model.
The Broader Transformation
BIOiSIM represents a structural change in how the industry thinks about risk. Innovation no longer depends on attrition when a company can quantify its translational probability before spending hundreds of millions.
The fusion of AI and biological modelling is giving rise to a new economic logic in pharmaceuticals. It is one where foresight, scalability, and equity define competitiveness. VeriSIM Life's experiment with the future of R&D is already underway. As Varshney says, it begins with a simple premise: “The goal is to make drug development more humane, more predictive, and more accessible — a process that serves both science and society.”
Find out more about the winners and finalists at the Reuters Events Global Pharma Awards 2025 - visit the website here.
